Source-grounded facts extracted from Arcutis Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Robert Lisicki was appointed as interim chief commercial officer at Arcutis Biotherapeutics, Inc..
“has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards’ departure from the Company on August 21, 2026.”
L. Todd Edwards resigned as chief commercial officer at Arcutis Biotherapeutics, Inc..
“On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.”
Arcutis Biotherapeutics, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company's named executive officers at the 2026-06-05 meeting.
“Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”
Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.
“Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026”
Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected at the 2026-06-05 meeting.
“Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected”
Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2026 results: revenue $105.4 million.
“--- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update • Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 • Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of”
David Topper departed as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“Mr. Topper will continue to serve as the Company’s Chief Financial Officer until the effective date of Ms. Vairavan’s appointment and will provide transition support through his departure on May 15, 2025.”
Latha Vairavan was appointed as Senior Vice President and Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“On April 10, 2025, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of Latha Vairavan, the Company’s current Vice President, Finance and Corporate Controller, as the Company’s Senior Vice President and Chief Financial Officer, effective immediately prior to the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission.”
Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.6 million.
“3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 | arcutis.com First Quarter 2024 Summary Financial Results Product revenues for the quarter ended March 31, 2024 were $21.6 million compared to $2.8 million for the corresponding period in 2023. Revenues for the quarter were $15.0 million for ZORYVE (roflumilast) cream 0.3% and $6.5 million for ZORYVE”
John Smither resigned as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.”
John Smither changed role as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.”
David Topper was appointed as Chief Financial Officer at Arcutis Biotherapeutics, Inc..
“On April 10, 2024, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of David Topper as the Company’s Chief Financial Officer, effective as of April 10, 2024.”
Arcutis Biotherapeutics, Inc. entered into License Agreement with Sato Pharmaceutical Co., Ltd. valued at an upfront payment of $25 million (effective 2024-02-27).
“On February 27, 2024, Arcutis Biotherapeutics, Inc. (“Arcutis” or the “Company”) entered into a License Agreement (the “License Agreement”) with Sato Pharmaceutical Co., Ltd. (“Sato”).”
Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2023 results: revenue $13.5 million.
“--- Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Q4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven by sequential improvement in gross-to-net (GTN) in the”
Arcutis Biotherapeutics, Inc. reported quarter ended September 30, 2023 results: revenue net product revenues for ZORYVE (roflumilast) cream 0.3% were $8.1 million.
“2023 Financial Results and Provides Business Update • Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in gross-to-net (GTN) down to the low 70 percent range, as well as”
Arcutis Biotherapeutics, Inc. reported three months ended September 30, 2023 results: revenue total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and oth.
“While the Company has not finalized its full financial results as of and for the quarter ended September 30, 2023, the Company expects to report that for the three months ended September 30, 2023, the Company generated total revenues of approximately $38.1 million, which comprised net product revenue of approximately $8.1 million and other revenue of $30.0 million.”
Ayisha Jeter changed role as Senior Vice President, Marketing and Market Access at Arcutis Biotherapeutics, Inc..
“In connection with the appointment of Mr. Edwards, Ms. Jeter will be promoted to Senior Vice President, Marketing and Market Access, effective as of September 27, 2023.”
L. Todd Edwards was appointed as Chief Commercial Officer at Arcutis Biotherapeutics, Inc..
“On September 27, 2023, Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) announced the appointment of L. Todd Edwards as the Company’s Chief Commercial Officer, effective as of September 27, 2023.”
John Smither was appointed as interim chief financial officer at Arcutis Biotherapeutics, Inc..
“announcing the appointment of John Smither as the Company’s interim chief financial officer, effective as of August 31, 2023”
John Smither was appointed as interim chief financial officer at Arcutis Biotherapeutics, Inc..
“The Company has commenced a search for a permanent chief financial officer and has appointed John Smither, who previously served as the Company’s chief financial officer from May 2019 until his retirement in March 2021, as interim chief financial officer, effective upon Mr. Burrows’ departure from the Company on August 31, 2023.”
Scott Burrows resigned as chief financial officer at Arcutis Biotherapeutics, Inc..
“On August 15, 2023, Scott Burrows notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer of the Company, effective as of August 31, 2023.”
Arcutis Biotherapeutics, Inc. entered into License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. valued at upfront payment of $30 million; potential development and regulatory milestone payments up to $24 mi (effective 2023-08-10).
“On August 10, 2023, Arcutis Biotherapeutics, Inc. ("Arcutis" or the "Company") entered into a License Agreement (the "License Agreement") with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Huadong"), a wholly owned subsidiary of Huadong Medicine Co., Ltd.”
Arcutis Biotherapeutics, Inc. reported quarter ended June 30, 2023 results: revenue $4.8 million.
“Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update • Achieved total revenues of $5.2 million in the second quarter of 2023.”
Arcutis Biotherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers at the 2023-05-31 meeting.
“Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers: Votes for Votes against Abstentions Broker Non-Votes 43,770,313 7,343,874 28,772 3,771,693”
Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-31 meeting.
“Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023: Votes for Votes against Abstentions Broker Non-Votes 54,541,027 358,765 14,860 —”
Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class II directors to hold office until the 2026 annual meeting or until their respective successor is elected at the 2023-05-31 meeting.
“Proposal 1. The election of three Class II directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected: Nominee Votes for Votes withheld Broker Non-Votes Patrick J. Heron 44,208,982 6,933,977 3,771,693 Neha Krishnamohan 50,425,906 717,053 3,771,693 Todd Franklin Watanabe 45,416,267 5,726,692 3,771,693”
Ayisha Jeter was appointed as Interim Chief Commercial Officer at Arcutis Biotherapeutics, Inc..
“The Company has commenced a search for a permanent chief commercial officer and has appointed Ayisha Jeter, who has served as the Company’s Vice President of Market Access since joining the Company in June 2020, as interim chief commercial officer during the transition period.”
Kenneth Lock resigned as Senior Vice President and Chief Commercial Officer at Arcutis Biotherapeutics, Inc..
“On May 22, 2023, Kenneth Lock notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as Senior Vice President and Chief Commercial Officer of the Company, effective as of June 2, 2023, to attend to personal matters.”
Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $2.8 million.
“by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update • Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter • Continued expansion of commercial payer coverage”
Arcutis Biotherapeutics, Inc. reported the year ended December 31, 2022 results: revenue $3.7 million.
“Net product revenues for the year ended December 31, 2022 were $3.7 million.”
Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2022 results: revenue $3.0 million.
“Net product revenues for the quarter ended December 31, 2022 related to sales of ZORYVE were $3.0 million driven by unit demand.”
Arcutis Biotherapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
“Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) issued a press release relating to its financial results for the quarter ended September 30, 2022.”
Neha Krishnamohan was appointed as Class III Director and Audit Committee Member at Arcutis Biotherapeutics, Inc..
“Effective as of September 2, 2022, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) directors to ten (10) directors and appointed Neha Krishnamohan to the Board as a new Class III director and as a member of the Audit Committee of the Board (the “Audit Committee”).”
Ricky Sun resigned as Director at Arcutis Biotherapeutics, Inc..
“Mr. Leonard fills the vacancy created by the resignation of Ricky Sun, Ph.D. who resigned from the Board effective September 2, 2021.”
Keith R. Leonard Jr. was appointed as Class I director at Arcutis Biotherapeutics, Inc..
“On September 2, 2021, the Board of Directors (the “Board”) of Arcutis Biotherapeutics, Inc. (the “Company” or “Arcutis”) appointed Keith R. Leonard Jr. as a Class I director with a term expiring at the Company’s 2024 Annual Meeting of Stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.